Co-Diagnostics shares rise 13.29% intraday after Maxim Group initiates 'Buy' rating with $1.50 target.

Co-Diagnostics (CODX) surged 13.29% intraday following Maxim Group’s initiation of coverage with a 'Buy' rating and a $1.50 price target, representing over 300% upside from its $0.35 price. The firm highlighted the company’s PCR Pro diagnostic platform as a "paradigm-shifting" technology, capable of delivering rapid, low-cost RT-PCR tests for respiratory illnesses and tuberculosis. This upgrade contrasted with HC Wainwright’s recent 'Neutral' rating and D. Boral Capital’s reduced price targets, but aligned with prior 'Buy' ratings from the latter firm. Despite Co-Diagnostics reporting a 83% revenue decline in Q3 2025, the analyst action emphasized the platform’s potential to expand market access, particularly in U.S. respiratory diagnostics and India’s tuberculosis testing. The stock’s sharp intraday rally reflects renewed investor optimism driven by Maxim Group’s endorsement of the company’s innovative pipeline and global distribution partnerships.